WALTHAM, MA – January 8, 2008 -- PerkinElmer Life and Analytical Sciences, a global leader in life science research, drug discovery and cellular science, launched a new family of Tri-Carb^® liquid scintillation analyzers (LSAs), essential instruments for academic, drug discovery, environmental and government researchers who require radiometric detection. A major step forward in automated sample tracking, the new family of Tri-Carb LSAs features a barcode reader system, an industry first in liquid scintillation analyzers.

“The advanced barcode reader technology integrated into the new Tri-Carb LSAs reduces errors in sample tracking and improves lab efficiency with enhanced sample screening and post-processing data analysis capabilities,” said Dr. Richard Eglen, President, Molecular Medicine, PerkinElmer Life and Analytical Sciences. “In addition, our patented and proven time-resolved liquid scintillation counting (TR-LSC^®) technology reduces electronic background, thereby increasing radioactivity detection sensitivity.”

Research labs use liquid scintillation analysis as an essential measurement tool for applications that require radioisotope tracers. With these new product technology innovations, researchers can screen against a target contaminant threshold and track thousands of samples taken each day with greater confidence in data accuracy and integrity. The new family of Tri-Carb LSAs will bring productivity improvements to a broad array of customers and application areas − from nuclear power plants that monitor for tritium levels in water produced by reactors; to homeland security facilities that screen urine and food in the event of contamination; to academic institutions that maintain active radiation safety programs.

The Tri-Carb LSA is available in four models, from basic to advanced capabilities, and offers capacity for add-on options:

• The 2810 base model is designed for a wide range of basic research applications
• The 2910 offers greater throughput and enhanced features, including extra protocol capacity, Replay sample recall and reprocessing and single/dual color-corrected DPM
• The 3110 provides many standard features including high sensitivity count mode, sample preview and region optimization
• The 3180 fully loaded model provides the highest sensitivity counting and is especially well-suited for environmental analysis

As further demonstration of its commitment to the radiometric detection industry, PerkinElmer has also launched the new WIZARD²_™ Automatic Gamma Counter. This next-generation gamma counter for academic, nuclear medicine and pharmaceutical researchers features a user-friendly interface system with a package of advanced technology features, including touch-screen operation, enhanced security options, built-in PC with LAN and USB connections, and a Windows^® operating platform.

For more information about the launch of the family of Tri-Carb LSAs, visit www.perkinelmer.com.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer Inc.’s Life and Analytical Sciences business unit provides fully integrated, innovative solutions, leveraging deep scientific expertise and dedication to fulfilling customer needs to help scientists advance the pace and precision of their research and testing. It is a leading provider of diagnostic and detection instruments, reagents, software and services for advanced cellular science research and drug discovery, genetic screening, medical imaging, environmental, quality assurance and the health sciences industries.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.